Supernus Current Liabilities vs Operating Margin Analysis
SUPN Stock | USD 28.87 0.13 0.45% |
Trend analysis of Supernus Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 154.7 M, Total Stockholder Equity of 967.6 M, Property Plant And Equipment Net of 44.7 M or Retained Earnings of 506.7 M provides information on Supernus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Supernus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Supernus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Supernus |
About Supernus Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Supernus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Supernus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Supernus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Supernus currently owns. An asset can also be divided into two categories, current and non-current.
Supernus Pharmaceuticals Balance Sheet Chart
Supernus Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Supernus Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Supernus Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 19th of April 2024, Non Currrent Assets Other is likely to grow to about 8.9 M, while Common Stock Shares Outstanding is likely to drop about 42.6 M. Add Fundamental
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Assets
Total assets refers to the total amount of Supernus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Supernus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 19th of April 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 23.4M | 7.1M | 2.4M | 2.3M | Depreciation And Amortization | 34.0M | 82.6M | 84.9M | 89.1M |
Supernus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Supernus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Supernus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 53.8M | 53.7M | 54.4M | 61.7M | 55.5M | 42.6M | |
Total Assets | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Short Long Term Debt Total | 375.6M | 390.3M | 420.6M | 438.0M | 41.5M | 39.5M | |
Other Current Liab | 3.2M | 40.0M | 65.0M | 139.8M | 279.9M | 293.9M | |
Total Current Liabilities | 160.6M | 245.1M | 315.4M | 688.0M | 290.2M | 154.7M | |
Total Stockholder Equity | 595.4M | 744.9M | 815.9M | 886.2M | 921.5M | 967.6M | |
Property Plant And Equipment Net | 38.3M | 37.8M | 17.0M | 15.2M | 42.5M | 44.7M | |
Net Debt | 194.2M | 101.7M | 217.1M | 344.8M | (33.5M) | (31.9M) | |
Retained Earnings | 199.5M | 326.5M | 379.9M | 481.2M | 482.6M | 506.7M | |
Accounts Payable | 10.1M | 78.9M | 117.7M | 96.3M | 2.0M | 1.9M | |
Cash | 181.4M | 288.6M | 203.4M | 93.1M | 75.1M | 116.1M | |
Non Current Assets Total | 687.6M | 873.7M | 1.1B | 968.4M | 915.9M | 961.7M | |
Non Currrent Assets Other | 615K | 8.0M | (36.1M) | (10.0M) | 8.5M | 8.9M | |
Cash And Short Term Investments | 347.1M | 422.5M | 339.7M | 461.3M | 254.9M | 201.2M | |
Net Receivables | 87.3M | 140.9M | 148.9M | 165.5M | 144.2M | 151.4M | |
Common Stock Total Equity | 51K | 52K | 53K | 54K | 62.1K | 40.8K | |
Short Term Investments | 165.7M | 133.9M | 136.2M | 368.2M | 179.8M | 98.1M | |
Liabilities And Stockholders Equity | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Non Current Liabilities Total | 404.3M | 514.1M | 557.9M | 128.3M | 197.3M | 179.2M | |
Inventory | 26.6M | 48.3M | 86.0M | 91.5M | 77.4M | 81.3M | |
Other Current Assets | 11.6M | 18.7M | 27.0M | 15.8M | 16.7M | 8.5M | |
Other Stockholder Equity | 388.4M | 409.3M | 434.3M | 408.1M | 439.5M | 279.8M | |
Total Liab | 564.9M | 759.2M | 873.3M | 816.3M | 487.5M | 333.9M | |
Property Plant And Equipment Gross | 38.3M | 37.8M | 33.4M | 28.2M | 28.9M | 30.4M | |
Total Current Assets | 472.6M | 630.4M | 601.6M | 734.2M | 493.1M | 305.3M | |
Accumulated Other Comprehensive Income | 7.4M | 9.0M | 1.5M | (3.2M) | (593K) | (563.4K) | |
Intangible Assets | 24.8M | 442.3M | 784.7M | 702.5M | 599.9M | 629.9M | |
Common Stock | 51K | 52K | 53K | 54K | 55K | 42.0K | |
Other Liab | 28.7M | 123.8M | 137.4M | 92.3M | 106.2M | 111.5M | |
Other Assets | 32.7M | 259.7M | 13.9M | 10.9M | 12.5M | 11.9M | |
Long Term Debt | 329.5M | 345.2M | 361.8M | 379.3M | 436.1M | 457.9M | |
Property Plant Equipment | 17.1M | 37.8M | 52.3M | 44.1M | 50.7M | 53.2M | |
Net Tangible Assets | 570.6M | 302.6M | (86.4M) | 66.7M | 76.7M | 72.9M | |
Good Will | 24.8M | 77.9M | 117.5M | 117.0M | 134.6M | 141.3M | |
Retained Earnings Total Equity | 199.5M | 326.5M | 379.9M | 481.2M | 553.4M | 581.1M | |
Capital Surpluse | 388.4M | 409.3M | 434.3M | 408.1M | 469.3M | 352.1M |
Supernus Pharmaceuticals Investors Sentiment
The influence of Supernus Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Supernus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Supernus Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Supernus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Supernus Pharmaceuticals' short interest history, or implied volatility extrapolated from Supernus Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.